BMI View: Domestic generic drugmakers will be at a distinct advantage under Sri Lanka’s proposed
national medicinal policy. With directives boosting generic drug sales through generic substitution, local
pharmaceutical companies will be further assisted as the government aims to use the policy to reduce
medicine imports. We highlight that these changes will come at the expense of drugmakers in India and
Bangladesh, which have been a key source of pharmaceutical imports into Sri Lanka.
Headline Expenditure Projections
? Pharmaceuticals: LKR82.88bn (USD609mn) in 2015 to LKR90.57bn (USD612mn) in 2016.
? Healthcare: LKR308.39bn (USD2.27bn) in 2015 to LKR335.42bn (USD2.26bn) in 2016.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Sri Lanka 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Sri Lanka 2012-2020) 12
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Sri Lanka 2012-2020) 15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Sri Lanka 2012-2020) 15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Sri Lanka 2012-2020) 16
Prescription Drug Market Forecast 16
Pharmaceutical Trade Forecast 18
Table: Pharmaceutical Trade Data And Forecasts (Sri Lanka 2014-2020) 20
Table: Pharmaceutical Trade Data And Forecasts local currency (Sri Lanka 2014-2020) 20
Industry Risk Reward Indices 21
Asia Pacific Risk/Reward Index 21
Sri Lanka - Risk/Reward Index 27
Rewards 27
Risks 27
Regulatory Review 28
Intellectual Property Issues 31
Pricing And Reimbursement Regimes 32
Market Overview 34
Healthcare Sector 34
Clinical Trials 38
Epidemiology 39
Competitive Landscape 45
Research-Based Industry 45
Table: Multinational Market Activity 46
Pharmaceutical Distribution 47
Pharmaceutical Retail Sector 48
Company Profile 49
GlaxoSmithKline 49
Hemas Holdings 52
State Pharmaceuticals Corporation (SPC) 55
Demographic Forecast 58
Demographic Outlook 58
Table: Population Headline Indicators (Sri Lanka 1990-2025) 59
Table: Key Population Ratios (Sri Lanka 1990-2025) 59
Table: Urban/Rural Population & Life Expectancy (Sri Lanka 1990-2025) 60
Table: Population By Age Group (Sri Lanka 1990-2025) 60
Table: Population By Age Group % (Sri Lanka 1990-2025) 61
Glossary 63
Methodology 65
Pharmaceutical Expenditure Forecast Model 65
Healthcare Expenditure Forecast Model 65
Notes On Methodology 66
Risk/Reward Index Methodology 67
Index Overview 68
Table: Pharmaceutical Risk/Reward Index Indicators 68
Indicator Weightings 69

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Sri Lanka 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Sri Lanka 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Sri Lanka 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Sri Lanka 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Sri Lanka 2012-2020)
Table: Pharmaceutical Trade Data And Forecasts (Sri Lanka 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (Sri Lanka 2014-2020)
Table: Multinational Market Activity
Table: Population Headline Indicators (Sri Lanka 1990-2025)
Table: Key Population Ratios (Sri Lanka 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Sri Lanka 1990-2025)
Table: Population By Age Group (Sri Lanka 1990-2025)
Table: Population By Age Group % (Sri Lanka 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators